NCT00984282 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 207
- group Id
- BG001
- value
- 210
- group Id
- BG002
- value
- 417
- units
- Participants
- groups
- description
- Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (12 hours apart without food), 28 days comprise a cycle.
- id
- BG000
- title
- Sorafenib (Nexavar, BAY43-9006)
- description
- Participants received 2 tablets of Sorafenib-matching placebo orally twice daily (12 hours apart without food), 28 days comprise a cycle.
- id
- BG001
- title
- Placebo
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 11.2
- value
- 61.5
- group Id
- BG001
- spread
- 11.7
- value
- 62.0
- group Id
- BG002
- spread
- 11.4
- value
- 61.8
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 80
- group Id
- BG001
- value
- 81
- group Id
- BG002
- value
- 161
- title
- < 60 years
- measurements
- group Id
- BG000
- value
- 127
- group Id
- BG001
- value
- 129
- group Id
- BG002
- value
- 256
- title
- >= 60 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 103
- group Id
- BG001
- value
- 115
- group Id
- BG002
- value
- 218
- title
- Female
- measurements
- group Id
- BG000
- value
- 104
- group Id
- BG001
- value
- 95
- group Id
- BG002
- value
- 199
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 124
- group Id
- BG001
- value
- 125
- group Id
- BG002
- value
- 249
- title
- Europe
- measurements
- group Id
- BG000
- value
- 36
- group Id
- BG001
- value
- 36
- group Id
- BG002
- value
- 72
- title
- North America
- measurements
- group Id
- BG000
- value
- 47
- group Id
- BG001
- value
- 49
- group Id
- BG002
- value
- 96
- title
- Asia
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Geographic region
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- title
- Missing
- measurements
- group Id
- BG000
- value
- 130
- group Id
- BG001
- value
- 129
- group Id
- BG002
- value
- 259
- title
- 0
- measurements
- group Id
- BG000
- value
- 69
- group Id
- BG001
- value
- 74
- group Id
- BG002
- value
- 143
- title
- 1
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 13
- title
- 2
- description
- The ECOG PS required for the study was 0 (fully active), 1 (restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature), or 2 (ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours)
- param Type
- COUNT_OF_PARTICIPANTS
- title
- ECOG (Eastern Cooperative Oncology Group) performance status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 178
- group Id
- BG001
- value
- 181
- group Id
- BG002
- value
- 359
- title
- Lung
- categories
- measurements
- group Id
- BG000
- value
- 113
- group Id
- BG001
- value
- 101
- group Id
- BG002
- value
- 214
- title
- Lymph node
- categories
- measurements
- group Id
- BG000
- value
- 57
- group Id
- BG001
- value
- 56
- group Id
- BG002
- value
- 113
- title
- Bone
- description
- Participants could have had more than one site.
- param Type
- NUMBER
- title
- Site of target/nontarget lesions at baseline - organ class
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 207
- group Id
- BG001
- value
- 210
- group Id
- BG002
- value
- 417
- units
- Participants
- groups
- description
- Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (12 hours apart without food), 28 days comprise a cycle.
- id
- BG000
- title
- Sorafenib (Nexavar, BAY43-9006)
- description
- Participants received 2 tablets of Sorafenib-matching placebo orally twice daily (12 hours apart without food), 28 days comprise a cycle.
- id
- BG001
- title
- Placebo
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 11.2
- value
- 61.5
- group Id
- BG001
- spread
- 11.7
- value
- 62.0
- group Id
- BG002
- spread
- 11.4
- value
- 61.8
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 80
- group Id
- BG001
- value
- 81
- group Id
- BG002
- value
- 161
- title
- < 60 years
- measurements
- group Id
- BG000
- value
- 127
- group Id
- BG001
- value
- 129
- group Id
- BG002
- value
- 256
- title
- >= 60 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 103
- group Id
- BG001
- value
- 115
- group Id
- BG002
- value
- 218
- title
- Female
- measurements
- group Id
- BG000
- value
- 104
- group Id
- BG001
- value
- 95
- group Id
- BG002
- value
- 199
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 124
- group Id
- BG001
- value
- 125
- group Id
- BG002
- value
- 249
- title
- Europe
- measurements
- group Id
- BG000
- value
- 36
- group Id
- BG001
- value
- 36
- group Id
- BG002
- value
- 72
- title
- North America
- measurements
- group Id
- BG000
- value
- 47
- group Id
- BG001
- value
- 49
- group Id
- BG002
- value
- 96
- title
- Asia
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Geographic region
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- title
- Missing
- measurements
- group Id
- BG000
- value
- 130
- group Id
- BG001
- value
- 129
- group Id
- BG002
- value
- 259
- title
- 0
- measurements
- group Id
- BG000
- value
- 69
- group Id
- BG001
- value
- 74
- group Id
- BG002
- value
- 143
- title
- 1
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 13
- title
- 2
- description
- The ECOG PS required for the study was 0 (fully active), 1 (restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature), or 2 (ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours)
- param Type
- COUNT_OF_PARTICIPANTS
- title
- ECOG (Eastern Cooperative Oncology Group) performance status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 178
- group Id
- BG001
- value
- 181
- group Id
- BG002
- value
- 359
- title
- Lung
- categories
- measurements
- group Id
- BG000
- value
- 113
- group Id
- BG001
- value
- 101
- group Id
- BG002
- value
- 214
- title
- Lymph node
- categories
- measurements
- group Id
- BG000
- value
- 57
- group Id
- BG001
- value
- 56
- group Id
- BG002
- value
- 113
- title
- Bone
- description
- Participants could have had more than one site.
- param Type
- NUMBER
- title
- Site of target/nontarget lesions at baseline - organ class
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle